DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Information source: Papageorgiou General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis

Intervention: ibandronate (Drug); teriparatide (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Papageorgiou General Hospital

Official(s) and/or principal investigator(s):
Efstathios Mitsopoulos, MD, Principal Investigator, Affiliation: Papageorgiou General Hospital, Thessaloniki, Greece


Hemodialysis patients with low bone density (total hip T-score <-2. 5) will be assigned to receive teriparatide (those with histologic confirmation of adynamic bone disease) or ibandronate (subjects with increased osteoclast number on bone biopsy). Follow-up period: one year. A second bone biopsy at the end of the study.

Clinical Details

Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Effects of ibandronate and teriparatide on bone mineral density and bone histology in HD patients.

Secondary outcome: Effects of ibandronate and teriparatide on other bone disease markers


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Bone mineral density (T-score<-2. 5)

- Adynamic bone disease for the teriparatide group

- Increased osteoclast number on bone biopsy (high turnover) for the ibandronate group

- Calcium greater than 8. 1 mg/dl

Exclusion Criteria:

- Suspected carcinoma

- Unstable clinical setting

Locations and Contacts

Papageorgiou General Hospital, Thessaloniki 56403, Greece
Additional Information

Starting date: July 2006
Last updated: October 28, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017